Predict cancer
immunotherapy
response
Predict cancer
immunotherapy response
Predict cancer
immunotherapy
response
From one blood draw
before the first dose
From one blood draw before the first dose
From one blood draw before the first dose
EVIIVE is a Zurich-based precision oncology company developing blood-based tests that tell pharma which patients will respond to specific immunotherapies.
Validation across the oncology ecosystem
Validation across the oncology ecosystem
Validation across the oncology ecosystem
Partnerships
EVIIVE has established multiple active engagements with leading biopharmaceutical companies.
Partnerships
EVIIVE has established multiple active engagements with leading biopharmaceutical companies.
Partnerships
EVIIVE has established multiple active engagements with leading biopharmaceutical companies.
Clinical evidence
Multi-center retrospective-prospective studies of EVIIVE across two leading IO regimens in metastatic melanoma.
Clinical evidence
Multi-center retrospective-prospective studies of EVIIVE across two leading IO regimens in metastatic melanoma.
Clinical evidence
Multi-center retrospective-prospective studies of EVIIVE across two leading IO regimens in metastatic melanoma.
Funding
EVIIVE is supported by top-tier Swiss life-sciences investors and 8 competitive grant programs.
Funding
EVIIVE is supported by top-tier Swiss life-sciences investors and 8 competitive grant programs.
Funding
EVIIVE is supported by top-tier Swiss life-sciences investors and 8 competitive grant programs.
Current landscape
01
Poor responder identification
>60%
Phase III immuno-oncology trials fail because responders cannot be reliably identified before enrollment.
02
Unpredictable patient outcomes
>50%
Patients receiving approved immunotherapies still do not respond.
Our Platform
Our Platform
Our Platform
EVIIVE measures response-driver signals carried by extracellular vesicles, the small membrane particles cells release into the bloodstream as part of normal communication. The platform reads a multi-parameter signature that reflects how the patient is poised to respond, before treatment starts.
Leadership
Leadership
Leadership
Co-Founder & CEO
Molecular immunologist and entrepreneur with deep expertise in EV diagnostics, translating immune insights into clinically meaningful solutions.
Co-Founder & CEO
Molecular immunologist and entrepreneur with deep expertise in EV diagnostics, translating immune insights into clinically meaningful solutions.
Co-Founder & CEO
Molecular immunologist and entrepreneur with deep expertise in EV diagnostics, translating immune insights into clinically meaningful solutions.
Co-Founder & CSO
Cancer immunologist, former University of Zurich professor, and scientific architect of EVIIVE’s diagnostic platform, translating pioneering biomarker discoveries into novel immuno-oncology diagnostics.
Co-Founder & CSO
Cancer immunologist, former University of Zurich professor, and scientific architect of EVIIVE’s diagnostic platform, translating pioneering biomarker discoveries into novel immuno-oncology diagnostics.
Co-Founder & CSO
Cancer immunologist, former University of Zurich professor, and scientific architect of EVIIVE’s diagnostic platform, translating pioneering biomarker discoveries into novel immuno-oncology diagnostics.
Strategic & Commercial Advisor
Life sciences entrepreneur and executive with 20+ years of experience across academia and the biotech industry.
Strategic & Commercial Advisor
Life sciences entrepreneur and executive with 20+ years of experience across academia and the biotech industry.
Strategic & Commercial Advisor
Life sciences entrepreneur and executive with 20+ years of experience across academia and the biotech industry.
Why EVIIVE
“A decade after the breakthrough of first-generation immunotherapy, the bottleneck for the next generation is less about the molecule. It is patient selection.”
Prof. Dr. med. Reinhard Dummer
Founding board member, European Association of Dermato-oncology,
Faculty member, European Society for Medical Oncology
Founding board member,
European Association of Dermato-oncology,
Faculty member, European Society for Medical Oncology
